Effect of the reduced glutathione antioxidation combined with conventional antiviral drugs on hepatic fibrosis in patient with hepatitis b cirrhosis

Liver cirrhosis caused by chronic hepatitis b is the most common type of cirrhosis in China, patients may be with different degrees of liver dysfunction, and severe cases may have upper gastrointestinal hemorrhage, hepatic encephalopathy, carcinogenesis, etc. There are extensive liver cell necrosis, connective tissue hyperplasia and fibrotic septum formation in the pathology of liver cirrhosis, which result in damage to the structure of the hepatic lobules and the formation of pseudolobules[1,2]. Liver fibrosis is the core factor leading to the occurrence and development of hepatitis b cirrhosis, the process of fibrosis also largely determines the ultimate outcome of patients[3,4], the role of clinical conventional antiviral treatment has limitations in inhibiting the process of fibrosis, and many scholars recommend to join other drugs to expand the curative effect. Reduced glutathione can participate in the process of oxidation reduction in vivo, also has the functions such as protecting liver function, promoting protein synthesis and bilirubin metabolism, and can be used for the adjuvant treatment of liver diseases[5,6]. In the study, reduced glutathione combined with conventional antiviral drugs was used for the treatment of patients with hepatitis b cirrhosis, and the roles were discussed from liver fibrosis indexes, inflammatory factors, oxidative stress and other aspects.